Volume | 2,220,138 |
|
|||||
News | - | ||||||
Day High | 2.03 | Low High |
|||||
Day Low | 1.91 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Coherus BioSciences Inc | CHRS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.03 | 1.91 | 2.03 | 1.93 | 2.02 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,360 | 2,220,138 | $ 1.94 | $ 4,310,329 | - | 1.4301 - 8.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:53:27 | 25 | $ 1.97 | USD |
Coherus BioSciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
214.93M | 111.36M | - | 257.24M | -237.89M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Coherus BioSciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.15 | 2.245 | 1.91 | 2.08 | 1,596,816 | -0.1805 | -8.40% |
1 Month | 2.38 | 2.61 | 1.91 | 2.29 | 1,729,724 | -0.4105 | -17.25% |
3 Months | 2.15 | 2.87 | 1.91 | 2.35 | 2,601,055 | -0.1805 | -8.40% |
6 Months | 3.25 | 3.73 | 1.4301 | 2.50 | 5,048,010 | -1.28 | -39.40% |
1 Year | 8.12 | 8.22 | 1.4301 | 3.30 | 4,056,090 | -6.15 | -75.75% |
3 Years | 14.90 | 19.32 | 1.4301 | 5.66 | 1,971,956 | -12.93 | -86.78% |
5 Years | 14.43 | 23.91 | 1.4301 | 9.13 | 1,636,929 | -12.46 | -86.35% |
Coherus BioSciences Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. |